BNP/PUT/GILEAD SCIENCES/60/0.1/17.01.25 Stock

DE000PC5C5B8

Real-time Boerse Frankfurt Warrants 01:20:58 2024-07-09 pm EDT
0.18 ^EUR	-5.26%

Current month	+11.76%
1 month	-32.14%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BNP/PUT/GILEAD SCIENCES/60/0.1/17.01.25

Latest news about GILEAD SCIENCES, INC.

RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating	07:37am	MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93	Jul. 08	MT
HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	Jul. 03	AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	Jul. 01	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-09	0.18	-5.26%
24-07-08	0.19	-5.00%
24-07-05	0.2	-4.76%
24-07-04	0.21	+10.53%
24-07-03	0.19	+11.76%

Real-time Boerse Frankfurt Warrants

Last update July 09, 2024 at 01:20 pm EDT

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	PUT
Underlying	GILEAD SCIENCES, INC.
Issuer	BNP Paribas
WKN	PC5C5B
ISIN	DE000PC5C5B8
Date issued	2024-02-21
Strike	60 $
Maturity	2025-01-17 (192 Days)
Parity	10 : 1
Emission price	0.22 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.37 €
Lowest since issue	0.12 €
Spread	0.01 €
Spread %	5.26%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company